Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Migraine

Free Subscription Articles published in Cephalalgia Retrieve available abstracts of 263 articles: HTML format

Single Articles

July 2022
1. BRANDT RB, Cnossen VM, Doesborg PG, Coo IF, et al
   Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.
   Cephalalgia. 2022;42:722-729.
   PubMed     Abstract available
   
   
   
2. ZHOU Y, Zhang F, Starcevic Manning M, Hu Z, et al
   Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
   Cephalalgia. 2022;42:749-760.
   PubMed     Abstract available
   
   
   June 2022
3. MAKAREVICIUS G, Ryliskiene K
   Successful treatment of primary headache associated with sexual activity using erenumab: Case report.
   Cephalalgia. 2022;42:680-683.
   PubMed     Abstract available
   
   
   
4. OLIVEIRA R, Placido M, Pereira L, Machado S, et al
   Headaches and the use of personal protective equipment in the general population during the COVID-19 pandemic.
   Cephalalgia. 2022;42:608-617.
   PubMed     Abstract available
   
   
   
5. PENSATO U, Baraldi C, Favoni V, Mascarella D, et al
   Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
   Cephalalgia. 2022;42:645-653.
   PubMed     Abstract available
   
   
   
6. RAIBIN K, Markus TE
   Cutaneous allodynia in pediatric and adolescent patients and their mothers: A comparative study.
   Cephalalgia. 2022;42:579-589.
   PubMed     Abstract available
   
   
   May 2022
7. SUDAT SE, Jacobson AS, Avins AL, Lipton RB, et al
   A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.
   Cephalalgia. 2022 May 31:3331024221104180. doi: 10.1177/03331024221104180.
   PubMed     Abstract available
   
   
   
8. CHRISTENSEN CG, Techlo TR, Kogelman LJ, Wegner Thorner L, et al
   Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria.
   Cephalalgia. 2022 May 29:3331024221094548. doi: 10.1177/03331024221094548.
   PubMed     Abstract available
   
   
   
9. EVERS S, Frese A, Summ O, Husstedt IW, et al
   Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
   Cephalalgia. 2022 May 27:3331024221103815. doi: 10.1177/03331024221103815.
   PubMed     Abstract available
   
   
   
10. MOUAANAKI SA, Carlsen LN, Bendtsen L, Jensen RH, et al
    Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center.
    Cephalalgia. 2022 May 27:3331024221104178. doi: 10.1177/03331024221104178.
    PubMed     Abstract available
    
    
    
11. VERHAGEN IE, Spaink HA, van der Arend BW, van Casteren DS, et al
    Validation of diagnostic ICHD-3 criteria for menstrual migraine.
    Cephalalgia. 2022 May 6:3331024221099031. doi: 10.1177/03331024221099031.
    PubMed     Abstract available
    
    
    
12. HELFENSTEIN C, Strupf M, Stefke A, Fraunberger B, et al
    Cyclic changes of sensory parameters in migraine patients.
    Cephalalgia. 2022 May 6:3331024221097932. doi: 10.1177/03331024221097932.
    PubMed     Abstract available
    
    
    
13. NOSER AE, Klages KL, Gamwell KL, Brammer CN, et al
    A systematic evaluation of primary headache management apps leveraging behavior change techniques.
    Cephalalgia. 2022;42:510-523.
    PubMed     Abstract available
    
    
    
14. CHIANG CC, Shahid AH, Harriott AM, Tietjen GE, et al
    Evaluation and treatment of headache associated with moyamoya disease - a narrative review.
    Cephalalgia. 2022;42:542-552.
    PubMed     Abstract available
    
    
    April 2022
15. GEPPETTI P, De Cesaris F, Benemei S, Cortelli P, et al
    Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
    Cephalalgia. 2022 Apr 26:3331024221093712. doi: 10.1177/03331024221093712.
    PubMed     Abstract available
    
    
    
16. MOHAMAD SAFIAI NI, Mohamad NA, Basri H, Inche Mat LN, et al
    High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis.
    Cephalalgia. 2022 Apr 17:3331024221092423. doi: 10.1177/03331024221092423.
    PubMed     Abstract available
    
    
    
17. PAN LH, Wang YF, Ling YH, Lai KL, et al
    Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study.
    Cephalalgia. 2022 Apr 11:3331024221080572. doi: 10.1177/03331024221080572.
    PubMed     Abstract available
    
    
    
18. NIKOLOVA S, Schwedt TJ, Li J, Wu T, et al
    T2* reduction in patients with acute post-traumatic headache.
    Cephalalgia. 2022;42.
    PubMed     Abstract available
    
    
    March 2022
19. DI ANTONIO S, Arendt-Nielsen L, Ponzano M, Bovis F, et al
    Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients.
    Cephalalgia. 2022 Mar 25:3331024221082506. doi: 10.1177/03331024221082506.
    PubMed     Abstract available
    
    
    
20. PETRUSIC I, Jovanovic V, Kovic V, Savic AM, et al
    P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study.
    Cephalalgia. 2022 Mar 25:3331024221090204. doi: 10.1177/03331024221090204.
    PubMed     Abstract available
    
    
    
21. BUTT JH, S Eddelien H, Kruuse C
    The headache and aura-inducing effects of sildenafil in patients with migraine with aura.
    Cephalalgia. 2022 Mar 25:3331024221088998. doi: 10.1177/03331024221088998.
    PubMed     Abstract available
    
    
    
22. MCALLISTER P, Kudrow D, Cady R, Hirman J, et al
    Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
    Cephalalgia. 2022 Mar 25:3331024221089567. doi: 10.1177/03331024221089567.
    PubMed     Abstract available
    
    
    
23. FERNANDEZ-DE-LAS-PENAS C, Navarro-Santana MJ, Curiel-Montero F, Plaza-Manzano G, et al
    Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Mar 25:3331024221084217. doi: 10.1177/03331024221084217.
    PubMed     Abstract available
    
    
    
24. DIENER HC, McAllister P, Jurgens TP, Kessler Y, et al
    Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
    Cephalalgia. 2022 Mar 25:3331024221076485. doi: 10.1177/03331024221076485.
    PubMed     Abstract available
    
    
    
25. ASHINA M, McAllister P, Cady R, Hirman J, et al
    Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
    Cephalalgia. 2022 Mar 18:3331024221077646. doi: 10.1177/03331024221077646.
    PubMed     Abstract available
    
    
    
26. WANG YF, Liao YC, Tzeng YS, Chen SP, et al
    Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura.
    Cephalalgia. 2022 Mar 18:3331024221080891. doi: 10.1177/03331024221080891.
    PubMed     Abstract available
    
    
    
27. KWON S, Gil YE, Lee MJ
    Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
    Cephalalgia. 2022 Mar 18:3331024221076481. doi: 10.1177/03331024221076481.
    PubMed     Abstract available
    
    
    
28. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The burden and health care use of patients with migraine and tension-type headache in post-conflict area of Serbia.
    Cephalalgia. 2022 Mar 18:3331024221082061. doi: 10.1177/03331024221082061.
    PubMed     Abstract available
    
    
    
29. HIRTZ C, Adam G, Raposo N, Fabre N, et al
    Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign.
    Cephalalgia. 2022 Mar 18:3331024221076484. doi: 10.1177/03331024221076484.
    PubMed     Abstract available
    
    
    
30. THURAIAIYAH J, Kokoti L, Al-Karagholi MA, Ashina M, et al
    Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies.
    Cephalalgia. 2022 Mar 18:3331024221077665. doi: 10.1177/03331024221077665.
    PubMed     Abstract available
    
    
    
31. CHOWDHURY D, Mundra A, Datta D, Duggal A, et al
    Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.
    Cephalalgia. 2022 Mar 8:3331024221082077. doi: 10.1177/03331024221082077.
    PubMed     Abstract available
    
    
    
32. VAZ JM, Alves BM, Duarte DB, Marques LA, et al
    Quality appraisal of existing guidelines for the management of headache disorders by the AGREE II's method.
    Cephalalgia. 2022;42:239-249.
    PubMed     Abstract available
    
    
    February 2022
33. MATAMALA-GOMEZ M, Bottiroli S, Sances G, Allena M, et al
    Facial expressions modulate pain perception in patients with chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075081. doi: 10.1177/03331024221075081.
    PubMed     Abstract available
    
    
    
34. SEBASTIANELLI G, Abagnale C, Casillo F, Cioffi E, et al
    Bimodal sensory integration in migraine: A study of the effect of visual stimulation on somatosensory evoked cortical responses.
    Cephalalgia. 2022 Feb 15:3331024221075073. doi: 10.1177/03331024221075073.
    PubMed     Abstract available
    
    
    
35. KIM J, Park CG, Chu MK
    Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075616. doi: 10.1177/03331024221075616.
    PubMed     Abstract available
    
    
    
36. STOVNER LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, et al
    FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024211067775. doi: 10.1177/03331024211067775.
    PubMed     Abstract available
    
    
    
37. NUOTTAMO ME, Happola P, Artto V, Hautakangas H, et al
    NCOR2 is a novel candidate gene for migraine-epilepsy phenotype.
    Cephalalgia. 2022 Feb 15:3331024211068065. doi: 10.1177/03331024211068065.
    PubMed     Abstract available
    
    
    
38. AL-KHAZALI HM, Younis S, Al-Sayegh Z, Ashina S, et al
    Prevalence of neck pain in migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Feb 15:3331024211068073. doi: 10.1177/03331024211068073.
    PubMed     Abstract available
    
    
    
39. MESSLINGER K, Neuhuber W, May A
    Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19.
    Cephalalgia. 2022;42:176-180.
    PubMed     Abstract available
    
    
    January 2022
40. NAJIB U, Smith T, Hindiyeh N, Saper J, et al
    Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
    Cephalalgia. 2022 Jan 9:3331024211068813. doi: 10.1177/03331024211068813.
    PubMed     Abstract available
    
    
    
41. MCGINLEY JS, Houts CR, Wirth RJ, Lipton RB, et al
    Measuring headache day severity using multiple features in daily diary designs.
    Cephalalgia. 2022;42:53-62.
    PubMed     Abstract available
    
    
    December 2021
42. ELIZAGARAY-GARCIA I, Carvalho GF, Szikszay TM, Adamczyk WM, et al
    Psychophysical testing in chronic migraine and chronic tension type headache: An observational study.
    Cephalalgia. 2021 Dec 7:3331024211060315. doi: 10.1177/03331024211060315.
    PubMed     Abstract available
    
    
    
43. OLIVEIRA AB, Mercante JPP, Peres MFP, Molina MDCB, et al
    Physical inactivity and headache disorders: Cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Cephalalgia. 2021;41:1467-1485.
    PubMed     Abstract available
    
    
    
44. NERI I, Menichini D, Monari F, Bascio LS, et al
    Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
    Cephalalgia. 2021;41:1492-1498.
    PubMed     Abstract available
    
    
    November 2021
45. CHRISTENSEN SL, Rasmussen RH, Cour S, Ernstsen C, et al
    Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models.
    Cephalalgia. 2021 Nov 24:3331024211053570. doi: 10.1177/03331024211053570.
    PubMed     Abstract available
    
    
    
46. MALEKIAN N, Bastani PB, Oveisgharan S, Nabaei G, et al
    Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial.
    Cephalalgia. 2021 Nov 17:3331024211058182. doi: 10.1177/03331024211058182.
    PubMed     Abstract available
    
    
    
47. CHHABRA N, Chiang CC, Di Nome MA, Houghton O, et al
    Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine.
    Cephalalgia. 2021 Nov 17:3331024211056286. doi: 10.1177/03331024211056286.
    PubMed     Abstract available
    
    
    
48. NEVERDAHL JP, Uglem M, Matre D, Hansen JO, et al
    Pain thresholds and suprathreshold pain after sleep restriction in migraine - A blinded crossover study.
    Cephalalgia. 2021 Nov 17:3331024211056565. doi: 10.1177/03331024211056565.
    PubMed     Abstract available
    
    
    
49. TOGHA M, Martami F, Jafari E, Ariyanfar S, et al
    The prevalence and characteristics of visceral autonomic symptoms among migraineurs: A population-based study.
    Cephalalgia. 2021 Nov 17:3331024211056849. doi: 10.1177/03331024211056849.
    PubMed     Abstract available
    
    
    
50. REUTER U, Ehrlich M, Gendolla A, Heinze A, et al
    Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
    Cephalalgia. 2021 Nov 7:3331024211053571. doi: 10.1177/03331024211053571.
    PubMed     Abstract available
    
    
    
51. PARAKRAMAWEERA R, Evans RW, Schor LI, Pearson SM, et al
    A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache.
    Cephalalgia. 2021;41:1298-1309.
    PubMed     Abstract available
    
    
    October 2021
52. HAPPOLA P, Gormley P, Nuottamo ME, Artto V, et al
    Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.
    Cephalalgia. 2021 Oct 14:3331024211045651. doi: 10.1177/03331024211045651.
    PubMed     Abstract available
    
    
    
53. OVEREEM LH, Peikert A, Hofacker MD, Kamm K, et al
    Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Cephalalgia. 2021 Oct 13:3331024211048765. doi: 10.1177/03331024211048765.
    PubMed     Abstract available
    
    
    
54. MESSINA R, Rocca MA, Valsasina P, Misci P, et al
    Clinical correlates of hypothalamic functional changes in migraine patients.
    Cephalalgia. 2021 Oct 13:3331024211046618. doi: 10.1177/03331024211046618.
    PubMed     Abstract available
    
    
    
55. KANG L, Tang W, Zhang Y, Zhang M, et al
    The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice.
    Cephalalgia. 2021 Oct 13:3331024211050036. doi: 10.1177/03331024211050036.
    PubMed     Abstract available
    
    
    
56. REUTER U, Krege JH, Lombard L, Gomez Valderas E, et al
    Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Cephalalgia. 2021 Oct 13:3331024211048507. doi: 10.1177/03331024211048507.
    PubMed     Abstract available
    
    
    
57. ALPUENTE A, Gallardo VJ, Asskour L, Caronna E, et al
    Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
    Cephalalgia. 2021 Oct 4:3331024211040467. doi: 10.1177/03331024211040467.
    PubMed     Abstract available
    
    
    
58. FRANK F, Ulmer H, Sidoroff V, Broessner G, et al
    CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2021;41.
    PubMed     Abstract available
    
    
    
59. TANHA HM, Martin NG, Whitfield JB, Nyholt DR, et al
    Association and genetic overlap between clinical chemistry tests and migraine.
    Cephalalgia. 2021;41.
    PubMed     Abstract available
    
    
    
60. GONZALEZ-QUINTANILLA V, Perez-Pereda S, Gonzalez-Suarez A, Madera J, et al
    Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases.
    Cephalalgia. 2021;41.
    PubMed     Abstract available
    
    
    
61. VAN CASTEREN DS, Verhagen IE, de Boer I, de Vries Lentsch S, et al
    E-diary use in clinical headache practice: A prospective observational study.
    Cephalalgia. 2021;41.
    PubMed     Abstract available
    
    
    September 2021
62. LOBO R, Wang M, Lobo S, Bahra A, et al
    Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache.
    Cephalalgia. 2021 Sep 27:3331024211044440. doi: 10.1177/03331024211044440.
    PubMed     Abstract available
    
    
    
63. KIM S, Lee SB, Hong YJ, Kim Y, et al
    The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea.
    Cephalalgia. 2021 Sep 27:3331024211044441. doi: 10.1177/03331024211044441.
    PubMed     Abstract available
    
    
    
64. CHOWDHURY D, Bansal L, Duggal A, Datta D, et al
    TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
    Cephalalgia. 2021 Sep 27:3331024211047454. doi: 10.1177/03331024211047454.
    PubMed     Abstract available
    
    
    
65. RAFFAELLI B, Terhart M, Overeem LH, Mecklenburg J, et al
    Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
    Cephalalgia. 2021 Sep 27:3331024211046617. doi: 10.1177/03331024211046617.
    PubMed     Abstract available
    
    
    
66. INAN LE, Inan N
    Greater occipital nerve block in migraine may have a place in migraine treatment.
    Cephalalgia. 2021 Sep 23:3331024211045644. doi: 10.1177/03331024211045644.
    PubMed    
    
    
    
67. BOTTIROLI S, Galli F, Ballante E, Pazzi S, et al
    Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse.
    Cephalalgia. 2021 Sep 20:3331024211039817. doi: 10.1177/03331024211039817.
    PubMed     Abstract available
    
    
    
68. PUTANANICKAL N, Gross EC, Orsini AL, Schmidt S, et al
    Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Cephalalgia. 2021 Sep 20:3331024211043792. doi: 10.1177/03331024211043792.
    PubMed     Abstract available
    
    
    
69. 
    CORRIGENDUM to 'Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis'.
    Cephalalgia. 2021 Sep 14:3331024211042798. doi: 10.1177/03331024211042798.
    PubMed    
    
    
    
70. SCHWEDT TJ, Lipton RB, Ailani J, Silberstein SD, et al
    Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Cephalalgia. 2021 Sep 14:3331024211042385. doi: 10.1177/03331024211042385.
    PubMed     Abstract available
    
    
    
71. IKEGAMI D, Navratilova E, Yue X, Moutal A, et al
    A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
    Cephalalgia. 2021 Sep 12:3331024211039813. doi: 10.1177/03331024211039813.
    PubMed     Abstract available
    
    
    August 2021
72. LIPTON RB, Dodick DW, Kudrow D, Reuter U, et al
    Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Cephalalgia. 2021 Aug 18:3331024211028966. doi: 10.1177/03331024211028966.
    PubMed     Abstract available
    
    
    
73. TFELT-HANSEN P, Jorgensen K, Diener HC
    Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
    Cephalalgia. 2021 Aug 18:3331024211029939. doi: 10.1177/03331024211029939.
    PubMed     Abstract available
    
    
    
74. CHRISTENSEN SL, Rasmussen RH, Ernstsen C, La Cour S, et al
    CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine.
    Cephalalgia. 2021 Aug 18:3331024211038884. doi: 10.1177/03331024211038884.
    PubMed     Abstract available
    
    
    
75. PENG KP, Schellong M, May A
    Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura.
    Cephalalgia. 2021 Aug 18:3331024211030499. doi: 10.1177/03331024211030499.
    PubMed     Abstract available
    
    
    
76. GIL-GOUVEIA R, Oliveira AG
    Are PROMs passing the message? A reflection with real-life migraine patients.
    Cephalalgia. 2021 Aug 18:3331024211034509. doi: 10.1177/03331024211034509.
    PubMed     Abstract available
    
    
    
77. ROZEN TD, Bhatt AA
    Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention.
    Cephalalgia. 2021 Aug 18:3331024211037277. doi: 10.1177/03331024211037277.
    PubMed     Abstract available
    
    
    
78. BEIER D, Callesen HE, Carlsen LN, Birkefoss K, et al
    Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis.
    Cephalalgia. 2021 Aug 18:3331024211034489. doi: 10.1177/03331024211034489.
    PubMed     Abstract available
    
    
    
79. MARTINELLI D, Arceri S, De Icco R, Allena M, et al
    BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
    Cephalalgia. 2021 Aug 18:3331024211034508. doi: 10.1177/03331024211034508.
    PubMed     Abstract available
    
    
    
80. MCGINLEY JS, Savord A, Houts CR, Wirth RJ, et al
    What do people want to know about "Growing Up with Migraine"? Results of a preference survey of people with lived experience to guide future research.
    Cephalalgia. 2021 Aug 18:3331024211038526. doi: 10.1177/03331024211038526.
    PubMed     Abstract available
    
    
    
81. AL-HASSANY L, Vries T, Carpay JA, MaassenVanDenBrink A, et al
    Could erectile dysfunction be a side effect of CGRP inhibition? A case report.
    Cephalalgia. 2021 Aug 18:3331024211037304. doi: 10.1177/03331024211037304.
    PubMed     Abstract available
    
    
    
82. REIDY BL, Peugh J, Hershey AD, Coffey CS, et al
    Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial.
    Cephalalgia. 2021 Aug 17:3331024211033551. doi: 10.1177/03331024211033551.
    PubMed     Abstract available
    
    
    
83. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The first prevalence study of primary headaches in adults in a post-conflict area of Serbia.
    Cephalalgia. 2021;41:959-967.
    PubMed     Abstract available
    
    
    
84. HUTCHINSON S, Silberstein SD, Blumenfeld AM, Lipton RB, et al
    Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Cephalalgia. 2021;41:979-990.
    PubMed     Abstract available
    
    
    
85. MEHTA DG, Garza I, Robertson CE
    Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities.
    Cephalalgia. 2021;41:1015-1026.
    PubMed     Abstract available
    
    
    July 2021
86. TFELT-HANSEN P
    Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
    Cephalalgia. 2021 Jul 18:3331024211028959. doi: 10.1177/03331024211028959.
    PubMed     Abstract available
    
    
    
87. ROXAS A JR, Quiles LE, Wang SJ
    Delivery of care for migraine in the Asian Oceanian region: A cross-sectional study.
    Cephalalgia. 2021 Jul 18:3331024211024153. doi: 10.1177/03331024211024153.
    PubMed     Abstract available
    
    
    
88. CERAMI C, Crespi C, Bottiroli S, Santi GC, et al
    High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients.
    Cephalalgia. 2021 Jul 13:3331024211027568. doi: 10.1177/03331024211027568.
    PubMed     Abstract available
    
    
    
89. AKERMAN S, Salvemini D, Romero-Reyes M
    Targeting reactive nitroxidative species in preclinical models of migraine.
    Cephalalgia. 2021 Jul 13:3331024211017884. doi: 10.1177/03331024211017884.
    PubMed     Abstract available
    
    
    
90. DAVIDSSON OB, Olofsson IA, Kogelman LJ, Andersen MA, et al
    Twenty-five years of triptans - a nationwide population study.
    Cephalalgia. 2021;41:894-904.
    PubMed     Abstract available
    
    
    June 2021
91. MACKENZIE KD, Stratton JR
    Response to letter to the Editor: Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021563. doi: 10.1177/03331024211021563.
    PubMed    
    
    
    
92. XU C, Bussiere J
    Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021569. doi: 10.1177/03331024211021569.
    PubMed    
    
    
    
93. WANG SJ, Roxas AA Jr, Saravia B, Kim BK, et al
    Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Cephalalgia. 2021 Jun 25:3331024211024160. doi: 10.1177/03331024211024160.
    PubMed     Abstract available
    
    
    
94. GERSTL L, Tadych N, Heinen F, Kainz C, et al
    Migraine and the development of additional psychiatric and pain disorders in the transition from adolescence to adulthood.
    Cephalalgia. 2021 Jun 23:3331024211021792. doi: 10.1177/03331024211021792.
    PubMed     Abstract available
    
    
    
95. BENBOW T, Cairns BE
    Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?
    Cephalalgia. 2021 Jun 20:3331024211017882. doi: 10.1177/03331024211017882.
    PubMed     Abstract available
    
    
    
96. FRESE A, Summ O, Evers S
    CGRP release in an experimental human trigeminal pain model.
    Cephalalgia. 2021 Jun 20:3331024211017250. doi: 10.1177/03331024211017250.
    PubMed     Abstract available
    
    
    
97. LENGYEL M, Hajdu D, Dobolyi A, Rosta J, et al
    TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons.
    Cephalalgia. 2021;41:827-838.
    PubMed     Abstract available
    
    
    
98. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.
    Cephalalgia. 2021;41:810-820.
    PubMed     Abstract available
    
    
    May 2021
99. COHEN-BARAK O, Radivojevic A, Jones A, Fiedler-Kelly J, et al
    Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
    Cephalalgia. 2021 May 17:3331024211007789. doi: 10.1177/03331024211007789.
    PubMed     Abstract available
    
    
    
100. GANTENBEIN AR, Agosti R, Gobbi C, Flugel D, et al
     Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.
     Cephalalgia. 2021 May 17:3331024211014616. doi: 10.1177/03331024211014616.
     PubMed     Abstract available
     
     
     
101. TASSORELLI C, Diener HC, Silberstein SD, Dodick DW, et al
     Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
     Cephalalgia. 2021 May 14:3331024211010413. doi: 10.1177/03331024211010413.
     PubMed     Abstract available
     
     
     
102. WILKINS AJ, Haigh SM, Mahroo OA, Plant GT, et al
     Photophobia in migraine: A symptom cluster?
     Cephalalgia. 2021 May 14:3331024211014633. doi: 10.1177/03331024211014633.
     PubMed     Abstract available
     
     
     
103. PAZDERA L, Cohen JM, Ning X, Campos VR, et al
     Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
     Cephalalgia. 2021 May 14:3331024211008401. doi: 10.1177/03331024211008401.
     PubMed     Abstract available
     
     
     
104. LIPTON RB, Burstein R, Buse DC, Dodick DW, et al
     Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
     Cephalalgia. 2021 May 13:3331024211010305. doi: 10.1177/03331024211010305.
     PubMed     Abstract available
     
     
     
105. 
     CORRIGENDUM to 'Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN'.
     Cephalalgia. 2021 May 5:3331024211015848. doi: 10.1177/03331024211015848.
     PubMed    
     
     
     
106. DIENER HC, Ashina M, Ritter S, Paiva Da Silva Lima G, et al
     Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
     Cephalalgia. 2021 May 3:3331024211010308. doi: 10.1177/03331024211010308.
     PubMed     Abstract available
     
     
     
107. YOUNG AS, Nham B, Bradshaw AP, Calic Z, et al
     Clinical, oculographic, and vestibular test characteristics of vestibular migraine.
     Cephalalgia. 2021 May 2:3331024211006042. doi: 10.1177/03331024211006042.
     PubMed     Abstract available
     
     
     
108. SCHWEDT TJ, Sahai-Srivastava S, Murinova N, Birlea M, et al
     Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial.
     Cephalalgia. 2021 May 2:3331024211006903. doi: 10.1177/03331024211006903.
     PubMed     Abstract available
     
     
     April 2021
109. CHONG CD, Berisha V, Ross K, Kahn M, et al
     Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data.
     Cephalalgia. 2021 Apr 29:333102421991819. doi: 10.1177/0333102421991819.
     PubMed     Abstract available
     
     
     
110. POHL H, Benemei S, Garcia-Azorin D, Dixon J, et al
     Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments.
     Cephalalgia. 2021 Apr 19:3331024211006048. doi: 10.1177/03331024211006048.
     PubMed     Abstract available
     
     
     
111. RAOOF N, Hoffmann J
     Diagnosis and treatment of idiopathic intracranial hypertension.
     Cephalalgia. 2021;41:472-478.
     PubMed     Abstract available
     
     
     
112. CERIANI CE, Silberstein SD
     Headache and rhinosinusitis: A review.
     Cephalalgia. 2021;41:453-463.
     PubMed     Abstract available
     
     
     March 2021
113. ROTHROCK JF, Diener HC
     Headache secondary to cerebrovascular disease.
     Cephalalgia. 2021 Mar 18:333102421999045. doi: 10.1177/0333102421999045.
     PubMed     Abstract available
     
     
     
114. ZHANG Y, Zhao X, Wang Y, Dong Z, et al
     Prevalence and characteristics of cough headache in a Chinese respiratory clinic.
     Cephalalgia. 2021;41:366-374.
     PubMed     Abstract available
     
     
     
115. VINOGRADOVA LV, Suleymanova EM, Medvedeva TM
     Transient loss of interhemispheric functional connectivity following unilateral cortical spreading depression in awake rats.
     Cephalalgia. 2021;41:353-365.
     PubMed     Abstract available
     
     
     February 2021
116. SHAH R, Assis F, Narasimhan B, Khachadourian V, et al
     Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial.
     Cephalalgia. 2021 Feb 25:333102421997766. doi: 10.1177/0333102421997766.
     PubMed     Abstract available
     
     
     
117. WANG X, Yin Z, Lian Y, Xu Y, et al
     Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.
     Cephalalgia. 2021 Feb 25:333102421997850. doi: 10.1177/0333102421997850.
     PubMed     Abstract available
     
     
     
118. BHAKTA M, Vuong T, Taura T, Wilson DS, et al
     Migraine therapeutics differentially modulate the CGRP pathway.
     Cephalalgia. 2021 Feb 24:333102420983282. doi: 10.1177/0333102420983282.
     PubMed     Abstract available
     
     
     
119. SOLLMANN N, Schandelmaier P, Weidlich D, Borner C, et al
     Patients with episodic migraine show increased T2 values of the trapezius muscles - an investigation by quantitative high-resolution magnetic resonance imaging.
     Cephalalgia. 2021 Feb 20:333102421996374. doi: 10.1177/0333102421996374.
     PubMed     Abstract available
     
     
     
120. SOUTHWELL J, Afridi SK
     The burden of migraine on acute and emergency services in a London teaching hospital.
     Cephalalgia. 2021 Feb 18:333102420981734. doi: 10.1177/0333102420981734.
     PubMed     Abstract available
     
     
     
121. DE TOMMASO M, Delussi M, Gentile E, Ricci K, et al
     Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients.
     Cephalalgia. 2021 Feb 16:333102421996345. doi: 10.1177/0333102421996345.
     PubMed     Abstract available
     
     
     
122. DRELLIA K, Kokoti L, Deligianni CI, Papadopoulos D, et al
     Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
     Cephalalgia. 2021 Feb 10:333102421989601. doi: 10.1177/0333102421989601.
     PubMed     Abstract available
     
     
     
123. WIENHOLTZ NKF, Christensen CE, Zhang DG, Coskun H, et al
     Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
     Cephalalgia. 2021 Feb 10:333102420975395. doi: 10.1177/0333102420975395.
     PubMed     Abstract available
     
     
     
124. TCHIVILEVA IE, Ohrbach R, Fillingim RB, Lim PF, et al
     Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
     Cephalalgia. 2021 Feb 9:333102421989268. doi: 10.1177/0333102421989268.
     PubMed     Abstract available
     
     
     
125. ASHINA M, Reuter U, Smith T, Krikke-Workel J, et al
     Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
     Cephalalgia. 2021 Feb 4:333102421989232. doi: 10.1177/0333102421989232.
     PubMed     Abstract available
     
     
     
126. LISICKI M, Figuerola ML, Bonamico L, Lew D, et al
     The prevalence of migraine in Argentina: A reappraisal.
     Cephalalgia. 2021 Feb 1:333102421989262. doi: 10.1177/0333102421989262.
     PubMed     Abstract available
     
     
     
127. CHO S, Cho SJ, Lee MJ, Park JW, et al
     Clinical characteristics of pre-attack symptoms in cluster headache: A large series of Korean patients.
     Cephalalgia. 2021;41:227-236.
     PubMed     Abstract available
     
     
     January 2021
128. DIENER HC, Ashina M, Durand-Zaleski I, Kurth T, et al
     Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.
     Cephalalgia. 2021 Jan 20:333102421989247. doi: 10.1177/0333102421989247.
     PubMed     Abstract available
     
     
     
129. CATARCI T
     Occipital ischaemic stroke after visual snow phenomenon - a case report.
     Cephalalgia. 2021 Jan 12:333102420985444. doi: 10.1177/0333102420985444.
     PubMed     Abstract available
     
     
     
130. VERHAGEN IE, van Casteren DS, Lentsch SV, Terwindt GM, et al
     Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study.
     Cephalalgia. 2021 Jan 11:333102420981739. doi: 10.1177/0333102420981739.
     PubMed     Abstract available
     
     
     
131. KARSAN N, Perez-Rodriguez A, Nagaraj K, Bose PR, et al
     The migraine postdrome: Spontaneous and triggered phenotypes.
     Cephalalgia. 2021 Jan 10:333102420975401. doi: 10.1177/0333102420975401.
     PubMed     Abstract available
     
     
     
132. MELO-CARRILLO A, Strassman AM, Schain AJ, Adams AM, et al
     Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
     Cephalalgia. 2021;41:17-32.
     PubMed     Abstract available
     
     
     
133. LEHMAN LL, Bruccoleri R, Danehy A, Swanson J, et al
     Adverse effects of erenumab on cerebral proliferative angiopathy: A case report.
     Cephalalgia. 2021;41:122-126.
     PubMed     Abstract available
     
     
     December 2020
134. ILJAZI A, Ashina H, Zhuang ZA, Lopez Lopez C, et al
     Hypersensitivity to calcitonin gene-related peptide in chronic migraine.
     Cephalalgia. 2020 Dec 15:333102420981666. doi: 10.1177/0333102420981666.
     PubMed     Abstract available
     
     
     
135. BEGASSE DE DHAEM O, Gharedaghi MH, Bain P, Hettie G, et al
     Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review.
     Cephalalgia. 2020 Dec 10:333102420977852. doi: 10.1177/0333102420977852.
     PubMed     Abstract available
     
     
     
136. STRANG-KARLSSON S, Alenius S, Nasanen-Gilmore P, Nurhonen M, et al
     Migraine in children and adults born preterm: A nationwide register linkage study.
     Cephalalgia. 2020 Dec 9:333102420978357. doi: 10.1177/0333102420978357.
     PubMed     Abstract available
     
     
     
137. POZO-ROSICH P, Coppola G, Pascual J, Schwedt TJ, et al
     How does the brain change in chronic migraine? Developing disease biomarkers.
     Cephalalgia. 2020 Dec 8:333102420974359. doi: 10.1177/0333102420974359.
     PubMed     Abstract available
     
     
     
138. SCHRAMM S, Tenhagen I, Schmidt B, Holle-Lee D, et al
     Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study.
     Cephalalgia. 2020 Dec 3:333102420977183. doi: 10.1177/0333102420977183.
     PubMed     Abstract available
     
     
     
139. IRIMIA P, Martinez-Valbuena I, Minguez-Olaondo A, Dominguez-Vivero C, et al
     Interictal amylin levels in chronic migraine patients: A case-control study.
     Cephalalgia. 2020 Dec 3:333102420977106. doi: 10.1177/0333102420977106.
     PubMed     Abstract available
     
     
     
140. LIPTON RB, Tepper SJ, Silberstein SD, Kudrow D, et al
     Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
     Cephalalgia. 2020 Dec 3:333102420973994. doi: 10.1177/0333102420973994.
     PubMed     Abstract available
     
     
     
141. WOOD ME, Burch RC, Hernandez-Diaz S
     Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine.
     Cephalalgia. 2020 Dec 3:333102420975394. doi: 10.1177/0333102420975394.
     PubMed     Abstract available
     
     
     
142. GROENKE BR, Daline IH, Nixdorf DR
     SUNCT/SUNA: Case series presenting in an orofacial pain clinic.
     Cephalalgia. 2020 Dec 3:333102420977292. doi: 10.1177/0333102420977292.
     PubMed     Abstract available
     
     
     November 2020
143. GOADSBY PJ, Blumenfeld AM, Lipton RB, Dodick DW, et al
     Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
     Cephalalgia. 2020 Nov 26:333102420970523. doi: 10.1177/0333102420970523.
     PubMed     Abstract available
     
     
     
144. GHANIZADA H, Iljazi A, Ashina H, Do TP, et al
     Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers.
     Cephalalgia. 2020 Nov 26:333102420970489. doi: 10.1177/0333102420970489.
     PubMed     Abstract available
     
     
     
145. ASHINA M, Dolezil D, Bonner JH, Zhou L, et al
     A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
     Cephalalgia. 2020 Nov 24:333102420970889. doi: 10.1177/0333102420970889.
     PubMed     Abstract available
     
     
     
146. VAN CASTEREN DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, et al
     Sex differences in prevalence of migraine trigger factors: A cross-sectional study.
     Cephalalgia. 2020 Nov 17:333102420974362. doi: 10.1177/0333102420974362.
     PubMed     Abstract available
     
     
     
147. WANG SJ, Wu JW
     Reversion from chronic migraine to episodic migraine: A new outcome measure.
     Cephalalgia. 2020 Nov 17:333102420974004. doi: 10.1177/0333102420974004.
     PubMed    
     
     
     
148. GOLLION C, Gazagnes J, Fabry V, Barbieux-Guillot M, et al
     Atrial fibrillation and migraine with aura in young adults with ischemic stroke.
     Cephalalgia. 2020 Nov 17:333102420970880. doi: 10.1177/0333102420970880.
     PubMed     Abstract available
     
     
     
149. CARVALHO GF, Luedtke K, Szikszay TM, Bevilaqua-Grossi D, et al
     Muscle endurance training of the neck triggers migraine attacks.
     Cephalalgia. 2020 Nov 17:333102420970184. doi: 10.1177/0333102420970184.
     PubMed     Abstract available
     
     
     
150. LACKOVIC J, Price TJ, Dussor G
     De novo protein synthesis is necessary for priming in preclinical models of migraine.
     Cephalalgia. 2020 Nov 17:333102420970514. doi: 10.1177/0333102420970514.
     PubMed     Abstract available
     
     
     
151. MASTRIA G, Mancini V, Cesare MD, Puma M, et al
     Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit.
     Cephalalgia. 2020 Nov 9:333102420968245. doi: 10.1177/0333102420968245.
     PubMed     Abstract available
     
     
     
152. DODICK DW, Doty EG, Aurora SK, Ruff DD, et al
     Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
     Cephalalgia. 2020 Nov 3:333102420966658. doi: 10.1177/0333102420966658.
     PubMed     Abstract available
     
     
     
153. KOPRUSZINSKI CM, Thornton P, Arnold J, Newton P, et al
     Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
     Cephalalgia. 2020 Nov 1:333102420966581. doi: 10.1177/0333102420966581.
     PubMed     Abstract available
     
     
     
154. PETRUSIC I, Zidverc-Trajkovic J
     Redefining types of migraine aura.
     Cephalalgia. 2020 Nov 1:333102420970186. doi: 10.1177/0333102420970186.
     PubMed    
     
     
     
155. LEVINE A, Vanderah TW, Largent-Milnes TM
     An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.
     Cephalalgia. 2020 Nov 1:333102420966984. doi: 10.1177/0333102420966984.
     PubMed     Abstract available
     
     
     October 2020
156. LINSTRA KM, Ibrahimi K, van Casteren DS, Wermer MJ, et al
     Pain perception in women with menstrually-related migraine.
     Cephalalgia. 2020 Oct 21:333102420966977. doi: 10.1177/0333102420966977.
     PubMed     Abstract available
     
     
     
157. ERNSTSEN C, Christensen SL, Olesen J, Kristensen DM, et al
     No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine.
     Cephalalgia. 2020 Oct 15:333102420963857. doi: 10.1177/0333102420963857.
     PubMed     Abstract available
     
     
     
158. RIST PM, Bernstein C, Kowalski M, Osypiuk K, et al
     Multimodal chiropractic care for migraine: A pilot randomized controlled trial.
     Cephalalgia. 2020 Oct 13:333102420963844. doi: 10.1177/0333102420963844.
     PubMed     Abstract available
     
     
     
159. ZELE AJ, Dey A, Adhikari P, Feigl B, et al
     Melanopsin hypersensitivity dominates interictal photophobia in migraine.
     Cephalalgia. 2020 Oct 12:333102420963850. doi: 10.1177/0333102420963850.
     PubMed     Abstract available
     
     
     
160. 
     Migraine Trust Virtual 2020 - Author index.
     Cephalalgia. 2020;40.
     PubMed    
     
     
     
161. PERES MF, Evers S
     Using social media and search engine data in headache research.
     Cephalalgia. 2020;40:1274-1275.
     PubMed    
     
     
     September 2020
162. ZAGAMI AS, Shaikh S, Mahns D, Lambert GA, et al
     A potential role for two brainstem nuclei in craniovascular nociception and the triggering of migraine headache.
     Cephalalgia. 2020 Sep 29:333102420960039. doi: 10.1177/0333102420960039.
     PubMed     Abstract available
     
     
     
163. KOPRUSZINSKI CM, Navratilova E, Swiokla J, Dodick DW, et al
     A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
     Cephalalgia. 2020 Sep 26:333102420959794. doi: 10.1177/0333102420959794.
     PubMed     Abstract available
     
     
     
164. GRECO R, Demartini C, Zanaboni AM, Tumelero E, et al
     Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study.
     Cephalalgia. 2020 Sep 23:333102420949201. doi: 10.1177/0333102420949201.
     PubMed     Abstract available
     
     
     
165. EVANS K, Romero H, Spierings EL, Katz N, et al
     The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments.
     Cephalalgia. 2020 Sep 22:333102420960020. doi: 10.1177/0333102420960020.
     PubMed     Abstract available
     
     
     
166. VIANA M, Sances G, Terrazzino S, Zecca C, et al
     Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study.
     Cephalalgia. 2020 Sep 21:333102420959786. doi: 10.1177/0333102420959786.
     PubMed     Abstract available
     
     
     
167. GIRICZ Z, Pertich A, Oze A, Puszta A, et al
     Visually guided associative learning in pediatric and adult migraine without aura.
     Cephalalgia. 2020 Sep 20:333102420958388. doi: 10.1177/0333102420958388.
     PubMed     Abstract available
     
     
     
168. TFELT-HANSEN P, Diener HC
     Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation.
     Cephalalgia. 2020 Sep 9:333102420956916. doi: 10.1177/0333102420956916.
     PubMed     Abstract available
     
     
     
169. MARTIN LF, Patwardhan AM, Jain SV, Salloum MM, et al
     Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial.
     Cephalalgia. 2020 Sep 9:333102420956711. doi: 10.1177/0333102420956711.
     PubMed     Abstract available
     
     
     
170. HANCI F, Kilinc YB, Kilinc E, Turay S, et al
     Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods.
     Cephalalgia. 2020 Sep 9:333102420957588. doi: 10.1177/0333102420957588.
     PubMed     Abstract available
     
     
     
171. GIANI L, Cecchini AP, Astengo A, Lauria G, et al
     Cluster headache not responsive to sumatriptan: A retrospective study.
     Cephalalgia. 2020 Sep 3:333102420956705. doi: 10.1177/0333102420956705.
     PubMed     Abstract available
     
     
     
172. SMITH JH
     Have you ever experienced a headache of any kind?
     Cephalalgia. 2020;40:1132-1133.
     PubMed    
     
     
     August 2020
173. SCHWARZ A, Ziegeler C, Daneshkhah S, May A, et al
     Predicting the outcome of the greater occipital nerve block - an observational study on migraine patients with and without musculoskeletal cervical impairment.
     Cephalalgia. 2020 Aug 31:333102420954518. doi: 10.1177/0333102420954518.
     PubMed     Abstract available
     
     
     
174. ALTAMURA C, Viticchi G, Fallacara A, Costa CM, et al
     Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura.
     Cephalalgia. 2020 Aug 31:333102420956692. doi: 10.1177/0333102420956692.
     PubMed     Abstract available
     
     
     
175. ALTIERI M, Fratino M, Maestrini I, Puma M, et al
     It is time to consider even chronic migraine as a real chronic disease.
     Cephalalgia. 2020 Aug 24:333102420953108. doi: 10.1177/0333102420953108.
     PubMed    
     
     
     
176. PLATZBECKER K, Timm FP, Ashina S, Houle TT, et al
     Migraine treatment and the risk of postoperative, pain-related hospital readmissions in migraine patients.
     Cephalalgia. 2020 Aug 24:333102420949857. doi: 10.1177/0333102420949857.
     PubMed     Abstract available
     
     
     
177. VILA-BALLO A, Marti-Marca A, Torres-Ferrus M, Alpuente A, et al
     Neurophysiological correlates of abnormal auditory processing in episodic migraine during the interictal period.
     Cephalalgia. 2020 Aug 24:333102420951509. doi: 10.1177/0333102420951509.
     PubMed     Abstract available
     
     
     
178. SCHULTE LH, Menz MM, Haaker J, May A, et al
     The migraineur's brain networks: Continuous resting state fMRI over 30 days.
     Cephalalgia. 2020 Aug 23:333102420951465. doi: 10.1177/0333102420951465.
     PubMed     Abstract available
     
     
     
179. ORI M, Arra G, Caricato M, Freccia R, et al
     Age-related features in vestibular migraine onset: A multiparametric analysis.
     Cephalalgia. 2020 Aug 19:333102420951505. doi: 10.1177/0333102420951505.
     PubMed     Abstract available
     
     
     
180. MASON BN, Wattiez AS, Balcziak LK, Kuburas A, et al
     Vascular actions of peripheral CGRP in migraine-like photophobia in mice.
     Cephalalgia. 2020 Aug 18:333102420949173. doi: 10.1177/0333102420949173.
     PubMed     Abstract available
     
     
     
181. 
     Corrigendum to "Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults".
     Cephalalgia. 2020 Aug 18:333102420952270. doi: 10.1177/0333102420952270.
     PubMed    
     
     
     
182. FRANK F, Faulhaber M, Messlinger K, Accinelli C, et al
     Migraine and aura triggered by normobaric hypoxia.
     Cephalalgia. 2020 Aug 13:333102420949202. doi: 10.1177/0333102420949202.
     PubMed     Abstract available
     
     
     
183. SHAO Q, Rascati KL, Lawson KA, Wilson JP, et al
     Patterns and predictors of opioid use among migraine patients at emergency departments: A retrospective database analysis.
     Cephalalgia. 2020 Aug 11:333102420946710. doi: 10.1177/0333102420946710.
     PubMed     Abstract available
     
     
     
184. SEDDIK AH, Branner JC, Ostwald DA, Schramm SH, et al
     The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany.
     Cephalalgia. 2020 Aug 6:333102420944842. doi: 10.1177/0333102420944842.
     PubMed     Abstract available
     
     
     July 2020
185. DIENER HC, Tassorelli C, Dodick DW, Silberstein SD, et al
     Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults.
     Cephalalgia. 2020 Jul 28:333102420941839. doi: 10.1177/0333102420941839.
     PubMed     Abstract available
     
     
     
186. LIU Y, Wang M, Bian X, Qiu E, et al
     Proposed modified diagnostic criteria for recurrent painful ophthalmoplegic neuropathy: Five case reports and literature review.
     Cephalalgia. 2020 Jul 28:333102420944872. doi: 10.1177/0333102420944872.
     PubMed     Abstract available
     
     
     
187. DE ICCO R, Fiamingo G, Greco R, Bottiroli S, et al
     Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study.
     Cephalalgia. 2020 Jul 26:333102420942230. doi: 10.1177/0333102420942230.
     PubMed     Abstract available
     
     
     
188. SAFFI H, Do TP, Hansen JM, Dodick DW, et al
     The migraine landscape on YouTube: A review of YouTube as a source of information on migraine.
     Cephalalgia. 2020 Jul 23:333102420943891. doi: 10.1177/0333102420943891.
     PubMed     Abstract available
     
     
     
189. BOJAZAR R, Do TP, Hansen JM, Dodick DW, et al
     Googling migraine: A study of Google as an information resource of migraine management.
     Cephalalgia. 2020 Jul 23:333102420942241. doi: 10.1177/0333102420942241.
     PubMed     Abstract available
     
     
     
190. DE BOER I, MaassenVanDenBrink A, Terwindt GM
     The potential danger of blocking CGRP for treating migraine in CADASIL patients.
     Cephalalgia. 2020 Jul 13:333102420941814. doi: 10.1177/0333102420941814.
     PubMed     Abstract available
     
     
     
191. TFELT-HANSEN P, Diener HC
     Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks.
     Cephalalgia. 2020 Jul 13:333102420941827. doi: 10.1177/0333102420941827.
     PubMed     Abstract available
     
     
     
192. PAN YJ, Chen YC, Lu SR, Juang KD, et al
     The influence of friendship on migraine in young adolescents: A social network analysis.
     Cephalalgia. 2020 Jul 7:333102420940700. doi: 10.1177/0333102420940700.
     PubMed     Abstract available
     
     
     June 2020
193. RUSTICHELLI C, Bellei E, Bergamini S, Monari E, et al
     Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study.
     Cephalalgia. 2020 Jun 26:333102420937742. doi: 10.1177/0333102420937742.
     PubMed     Abstract available
     
     
     
194. LAMBRU G, Elias LA, Yakkaphan P, Renton T, et al
     Migraine presenting as isolated facial pain: A prospective clinical analysis of 58 cases.
     Cephalalgia. 2020 Jun 17:333102420933277. doi: 10.1177/0333102420933277.
     PubMed     Abstract available
     
     
     
195. GRAZZI L, Usai S, Bolognini N, Grignani E, et al
     No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial.
     Cephalalgia. 2020 Jun 14:333102420931050. doi: 10.1177/0333102420931050.
     PubMed     Abstract available
     
     
     
196. LAI KL, Niddam DM, Fuh JL, Chen WT, et al
     Reply to letter to the editor: Insights into chronic migraine pathophysiology - what measures of gray matter reveal.
     Cephalalgia. 2020 Jun 14:333102420933262. doi: 10.1177/0333102420933262.
     PubMed    
     
     
     
197. WURTHMANN S, Nagel S, Hadaschik E, Schlott S, et al
     Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report.
     Cephalalgia. 2020 Jun 14:333102420933571. doi: 10.1177/0333102420933571.
     PubMed     Abstract available
     
     
     
198. DESOUZA DD, Cowan RP
     Insights into chronic migraine pathophysiology - what measures of gray matter reveal.
     Cephalalgia. 2020 Jun 14:333102420933263. doi: 10.1177/0333102420933263.
     PubMed    
     
     
     
199. BARBANTI P, Aurilia C, Egeo G, Fofi L, et al
     Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients.
     Cephalalgia. 2020 Jun 2:333102420929023. doi: 10.1177/0333102420929023.
     PubMed     Abstract available
     
     
     
200. TANG C, Unekawa M, Shibata M, Tomita Y, et al
     Characteristics of cortical spreading depression and c-Fos expression in transgenic mice having a mutation associated with familial hemiplegic migraine 2.
     Cephalalgia. 2020 Jun 2:333102420929028. doi: 10.1177/0333102420929028.
     PubMed     Abstract available
     
     
     
201. NIDDAM DM, Wang SJ
     Reply to Letter to the Editor, "Creatine loading for chronic migraine?"
     Cephalalgia. 2020 Jun 2:333102420931051. doi: 10.1177/0333102420931051.
     PubMed    
     
     
     
202. OSTOJIC SM
     Creatine loading for chronic migraine?
     Cephalalgia. 2020 Jun 2:333102420931055. doi: 10.1177/0333102420931055.
     PubMed    
     
     
     May 2020
203. VIANA M, Hougaard A, Phu Do T
     The depiction of migraine visual aura on the internet.
     Cephalalgia. 2020 May 27:333102420927027. doi: 10.1177/0333102420927027.
     PubMed     Abstract available
     
     
     
204. CHRISTENSEN SL, Munro G, Petersen S, Shabir A, et al
     ATP sensitive potassium (KATP) channel inhibition: A promising new drug target for migraine.
     Cephalalgia. 2020 May 16:333102420925513. doi: 10.1177/0333102420925513.
     PubMed     Abstract available
     
     
     
205. PAN LH, Wang YF, Lai KL, Chen WT, et al
     Mechanical punctate pain threshold is associated with headache frequency and phase in patients with migraine.
     Cephalalgia. 2020 May 16:333102420925540. doi: 10.1177/0333102420925540.
     PubMed     Abstract available
     
     
     April 2020
206. ILJAZI A, Ashina H, Lipton RB, Chaudhry B, et al
     Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis.
     Cephalalgia. 2020 Apr 29:333102420921855. doi: 10.1177/0333102420921855.
     PubMed     Abstract available
     
     
     
207. MARTINEZ JM, Hindiyeh N, Anglin G, Kalidas K, et al
     Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.
     Cephalalgia. 2020 Apr 27:333102420920642. doi: 10.1177/0333102420920642.
     PubMed    
     
     
     
208. REIDY BL, Riddle EJ, Powers SW, Slater SK, et al
     Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache.
     Cephalalgia. 2020 Apr 26:333102420920644. doi: 10.1177/0333102420920644.
     PubMed    
     
     
     
209. GUO S, Falkenberg K, Schytz HW, Caparso A, et al
     Low frequency activation of the sphenopalatine ganglion does not induce migraine-like attacks in migraine patients.
     Cephalalgia. 2020 Apr 22:333102420921156. doi: 10.1177/0333102420921156.
     PubMed    
     
     
     
210. LAI KL, Niddam DM, Fuh JL, Chen WT, et al
     Cortical morphological changes in chronic migraine in a Taiwanese cohort: Surface- and voxel-based analyses.
     Cephalalgia. 2020 Apr 16:333102420920005. doi: 10.1177/0333102420920005.
     PubMed    
     
     
     
211. HVEDSTRUP J, Kolding LT, Ashina M, Schytz HW, et al
     Increased neck muscle stiffness in migraine patients with ictal neck pain: A shear wave elastography study.
     Cephalalgia. 2020 Apr 15:333102420919998. doi: 10.1177/0333102420919998.
     PubMed    
     
     
     
212. AMANAT M, Ashrafi MR
     The use of anti-epileptic drugs in prevention of migraine in children and adolescents.
     Cephalalgia. 2020 Apr 10:333102420918526. doi: 10.1177/0333102420918526.
     PubMed    
     
     
     
213. GAKI E, Siapkara A, Morgan S, Branch S, et al
     Sodium valproate in paediatric migraine.
     Cephalalgia. 2020 Apr 10:333102420918527. doi: 10.1177/0333102420918527.
     PubMed    
     
     
     
214. DAGHLAS I, Rist PM, Chasman DI
     Effect of genetic liability to migraine on cognition and brain volume: A Mendelian randomization study.
     Cephalalgia. 2020 Apr 4:333102420916751. doi: 10.1177/0333102420916751.
     PubMed    
     
     
     March 2020
215. MARCUS SC, Shewale AR, Silberstein SD, Lipton RB, et al
     Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
     Cephalalgia. 2020 Mar 29:333102420915167. doi: 10.1177/0333102420915167.
     PubMed    
     
     
     
216. CHRISTENSEN SL, Ernstsen C, Olesen J, Kristensen DM, et al
     No central action of CGRP antagonising drugs in the GTN mouse model of migraine.
     Cephalalgia. 2020 Mar 29:333102420914913. doi: 10.1177/0333102420914913.
     PubMed    
     
     
     
217. FALKENBERG K, Bjerg HR, Olesen J
     Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients.
     Cephalalgia. 2020 Mar 26:333102420915166. doi: 10.1177/0333102420915166.
     PubMed    
     
     
     
218. TEPPER SJ, Ashina M, Reuter U, Brandes JL, et al
     Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
     Cephalalgia. 2020 Mar 26:333102420912726. doi: 10.1177/0333102420912726.
     PubMed    
     
     
     
219. PERENBOOM MJ, van de Ruit M, Zielman R, van den Maagdenberg AM, et al
     Enhanced pre-ictal cortical responsivity in migraine patients assessed by visual chirp stimulation.
     Cephalalgia. 2020 Mar 18:333102420912725. doi: 10.1177/0333102420912725.
     PubMed    
     
     
     
220. KARSAN N, Bose PR, Thompson C, Newman J, et al
     Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study.
     Cephalalgia. 2020 Mar 12:333102420910114. doi: 10.1177/0333102420910114.
     PubMed     Abstract available
     
     
     
221. MEYLAKH N, Marciszewski KK, Di Pietro F, Macefield VG, et al
     Altered regional cerebral blood flow and hypothalamic connectivity immediately prior to a migraine headache.
     Cephalalgia. 2020 Mar 12:333102420911623. doi: 10.1177/0333102420911623.
     PubMed     Abstract available
     
     
     
222. ILJAZI A, Chua A, Rich-Fiondella R, Veronesi M, et al
     Unrecognized challenges of treating status migrainosus: An observational study.
     Cephalalgia. 2020 Mar 12:333102420911461. doi: 10.1177/0333102420911461.
     PubMed     Abstract available
     
     
     
223. LIPTON RB, Marcus SC, Shewale AR, Dodick DW, et al
     Acute treatment patterns in patients with migraine newly initiating a triptan.
     Cephalalgia. 2020 Mar 5:333102420905307. doi: 10.1177/0333102420905307.
     PubMed     Abstract available
     
     
     
224. CHALMER MA, Olesen J
     Letter to the editor regarding proposed new diagnostic criteria for migraine.
     Cephalalgia. 2020 Mar 3:333102420911190. doi: 10.1177/0333102420911190.
     PubMed    
     
     
     February 2020
225. NIDDAM DM, Lai KL, Tsai SY, Lin YR, et al
     Brain metabolites in chronic migraine patients with medication overuse headache.
     Cephalalgia. 2020 Feb 25:333102420908579. doi: 10.1177/0333102420908579.
     PubMed     Abstract available
     
     
     
226. ASHINA M, Saper J, Cady R, Schaeffler BA, et al
     Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
     Cephalalgia. 2020 Feb 19:333102420905132. doi: 10.1177/0333102420905132.
     PubMed     Abstract available
     
     
     
227. HANSEN LC, Gaul C, Pogatzki-Zahn E, Baron R, et al
     Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists.
     Cephalalgia. 2020 Feb 17:333102420907593. doi: 10.1177/0333102420907593.
     PubMed     Abstract available
     
     
     
228. ALPUENTE A, Tassorelli C, Diener HC, Silberstein SD, et al
     Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition.
     Cephalalgia. 2020 Feb 14:333102420906843. doi: 10.1177/0333102420906843.
     PubMed     Abstract available
     
     
     
229. BORTE S, Zwart JA, Skogholt AH, Gabrielsen ME, et al
     Mitochondrial genome-wide association study of migraine - the HUNT Study.
     Cephalalgia. 2020 Feb 14:333102420906835. doi: 10.1177/0333102420906835.
     PubMed     Abstract available
     
     
     January 2020
230. HOLLAND PR, Sureda-Gibert P, Vila-Pueyo M
     Rapid uptake of sumatriptan into the brain: An ongoing question of blood-brain barrier permeability.
     Cephalalgia. 2020 Jan 30:333102420905131. doi: 10.1177/0333102420905131.
     PubMed    
     
     
     
231. HUANG C, Chen SP, Huang YH, Chen HY, et al
     HLA class I alleles are associated with clinic-based migraine and increased risks of chronic migraine and medication overuse.
     Cephalalgia. 2020 Jan 23:333102420902228. doi: 10.1177/0333102420902228.
     PubMed     Abstract available
     
     
     
232. PENG KP, May A
     Redefining migraine phases - a suggestion based on clinical, physiological, and functional imaging evidence.
     Cephalalgia. 2020 Jan 13:333102419898868. doi: 10.1177/0333102419898868.
     PubMed     Abstract available
     
     
     December 2019
233. MINEN MT, Morio K, Schaubhut KB, Powers SW, et al
     Focus group findings on the migraine patient experience during research studies and ideas for future investigations.
     Cephalalgia. 2019 Dec 23:333102419888230. doi: 10.1177/0333102419888230.
     PubMed     Abstract available
     
     
     
234. ARAYA EI, Turnes JM, Barroso AR, Chichorro JG, et al
     Contribution of intraganglionic CGRP to migraine-like responses in male and female rats.
     Cephalalgia. 2019 Dec 19:333102419896539. doi: 10.1177/0333102419896539.
     PubMed     Abstract available
     
     
     
235. MUZZI M, Zecchi R, Ranieri G, Urru M, et al
     Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: Implication for cluster headache treatment.
     Cephalalgia. 2019 Dec 18:333102419896370. doi: 10.1177/0333102419896370.
     PubMed     Abstract available
     
     
     
236. HVEDSTRUP J, Kolding LT, Younis S, Ashina M, et al
     Ictal neck pain investigated in the interictal state - a search for the origin of pain.
     Cephalalgia. 2019 Dec 18:333102419896369. doi: 10.1177/0333102419896369.
     PubMed     Abstract available
     
     
     
237. PENG KP, Ziegeler C, Basedau H, Wang SJ, et al
     We still have no data to change the diagnostic criteria for chronic migraine.
     Cephalalgia. 2019 Dec 15:333102419895772. doi: 10.1177/0333102419895772.
     PubMed    
     
     
     
238. GUGLIELMETTI M, Raggi A, Ornello R, Sacco S, et al
     The clinical and public health implications and risks of widening the definition of chronic migraine.
     Cephalalgia. 2019 Dec 15:333102419895777. doi: 10.1177/0333102419895777.
     PubMed     Abstract available
     
     
     
239. BRANDES JL, Diener HC, Dolezil D, Freeman MC, et al
     The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving >/=50%, >/=75%, and 100% response.
     Cephalalgia. 2019 Dec 9:333102419894559. doi: 10.1177/0333102419894559.
     PubMed     Abstract available
     
     
     
240. WARFVINGE K, Edvinsson L
     Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions.
     Cephalalgia. 2019 Dec 6:333102419893962. doi: 10.1177/0333102419893962.
     PubMed     Abstract available
     
     
     
241. MAITROT-MANTELET L, Hugon-Rodin J, Vatel M, Marcellin L, et al
     Migraine in relation with endometriosis phenotypes: Results from a French case-control study.
     Cephalalgia. 2019 Dec 6:333102419893965. doi: 10.1177/0333102419893965.
     PubMed     Abstract available
     
     
     
242. LAPP HS, Sabatowski R, Weidner K, Croy I, et al
     C-tactile touch perception in migraineurs - a case-control study.
     Cephalalgia. 2019 Dec 1:333102419889349. doi: 10.1177/0333102419889349.
     PubMed     Abstract available
     
     
     November 2019
243. POZO-ROSICH P, Torres-Ferrus M
     When does chronic migraine strike?
     Cephalalgia. 2019 Nov 22:333102419885375. doi: 10.1177/0333102419885375.
     PubMed    
     
     
     
244. BRANDES JL, Kudrow D, Yeung PP, Sakai F, et al
     Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
     Cephalalgia. 2019 Nov 21:333102419885905. doi: 10.1177/0333102419885905.
     PubMed     Abstract available
     
     
     
245. KNIEVEL K, Buchanan AS, Lombard L, Baygani S, et al
     Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
     Cephalalgia. 2019 Nov 19:333102419889350. doi: 10.1177/0333102419889350.
     PubMed     Abstract available
     
     
     
246. MARCONI E, Pecchioli S, Nica M, Colombo D, et al
     Epidemiology and determinants of chronic migraine: A real-world cohort study, with nested case-control analysis, in primary care in Italy.
     Cephalalgia. 2019 Nov 19:333102419889351. doi: 10.1177/0333102419889351.
     PubMed     Abstract available
     
     
     
247. ASHINA M, Kudrow D, Reuter U, Dolezil D, et al
     Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
     Cephalalgia. 2019 Nov 10:333102419888222. doi: 10.1177/0333102419888222.
     PubMed     Abstract available
     
     
     
248. AMANAT M, Togha M, Agah E, Ramezani M, et al
     Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial.
     Cephalalgia. 2019 Nov 10:333102419888485. doi: 10.1177/0333102419888485.
     PubMed     Abstract available
     
     
     
249. WOLF J, Danno D, Takeshima T, Vancleef LM, et al
     The relation between emotion regulation and migraine: A cross-cultural study on the moderating effect of culture.
     Cephalalgia. 2019 Nov 5:333102419885394. doi: 10.1177/0333102419885394.
     PubMed     Abstract available
     
     
     
250. YOUNIS S, Christensen CE, Toft NM, Soborg T, et al
     Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil.
     Cephalalgia. 2019 Nov 4:333102419882474. doi: 10.1177/0333102419882474.
     PubMed     Abstract available
     
     
     
251. PLANCHUELO-GOMEZ A, Garcia-Azorin D, Guerrero AL, Aja-Fernandez S, et al
     Structural connectivity alterations in chronic and episodic migraine: A diffusion magnetic resonance imaging connectomics study.
     Cephalalgia. 2019 Nov 1:333102419885392. doi: 10.1177/0333102419885392.
     PubMed     Abstract available
     
     
     October 2019
252. CHIANG CC, Starling AJ, Buras MR, Golafshar MA, et al
     A pilot exploratory study comparing the King-Devick test (KDT) during and between migraine attacks.
     Cephalalgia. 2019 Oct 29:333102419885381. doi: 10.1177/0333102419885381.
     PubMed     Abstract available
     
     
     
253. VGONTZAS A, Renthal W
     Migraine-associated gene expression in cell types of the central and peripheral nervous system.
     Cephalalgia. 2019 Oct 29:333102419877834. doi: 10.1177/0333102419877834.
     PubMed     Abstract available
     
     
     
254. PISANU C, Lundin E, Preisig M, Gholam-Rezaee M, et al
     Major depression subtypes are differentially associated with migraine subtype, prevalence and severity.
     Cephalalgia. 2019 Oct 24:333102419884935. doi: 10.1177/0333102419884935.
     PubMed     Abstract available
     
     
     
255. SHI S, Han Y, Wang D, Guo P, et al
     PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model.
     Cephalalgia. 2019 Oct 22:333102419883374. doi: 10.1177/0333102419883374.
     PubMed     Abstract available
     
     
     
256. XU J, Kong F, Buse DC
     Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies.
     Cephalalgia. 2019 Oct 21:333102419883355. doi: 10.1177/0333102419883355.
     PubMed     Abstract available
     
     
     
257. SCHULTE LH, Peng KP
     Current understanding of premonitory networks in migraine: A window to attack generation.
     Cephalalgia. 2019 Oct 15:333102419883375. doi: 10.1177/0333102419883375.
     PubMed     Abstract available
     
     
     
258. VAN OOSTERHOUT WP, Schoonman GG, Saal DP, Thijs RD, et al
     Abnormal cardiovascular response to nitroglycerin in migraine.
     Cephalalgia. 2019 Oct 9:333102419881657. doi: 10.1177/0333102419881657.
     PubMed     Abstract available
     
     
     
259. KAMM K, Straube A, Ruscheweyh R
     Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls.
     Cephalalgia. 2019;39:1535-1543.
     PubMed     Abstract available
     
     
     September 2019
260. TFELT-HANSEN P, Diener HC, Steiner TJ
     Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review.
     Cephalalgia. 2019 Sep 23:333102419877663. doi: 10.1177/0333102419877663.
     PubMed     Abstract available
     
     
     
261. CHALMER MA, Hansen TF, Lebedeva ER, Dodick DW, et al
     Proposed new diagnostic criteria for chronic migraine.
     Cephalalgia. 2019 Sep 22:333102419877171. doi: 10.1177/0333102419877171.
     PubMed     Abstract available
     
     
     January 2019
262. CHALMER MA, Hansen TF, Olesen J
     Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia.
     Cephalalgia. 2019;39:38-43.
     PubMed     Abstract available
     
     
     
263. MAGGIONI F, Toldo G, Terrin A, Mainardi F, et al
     Simultaneous bilateral visual auras: A case report.
     Cephalalgia. 2019;39:162-163.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: